verapamil has been researched along with Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous in 2 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy of pathways inhibition and the combined effect of Everolimus (mTOR inhibitor) and Verapamil (CYP3A inhibitor) in ovarian hyperstimulation syndrome (OHSS) need to be tested." | 7.83 | The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study. ( Dalkalitsis, A; Georgiou, I; Kitsou, C; Kosmas, I; Lazaros, L; Mynbaev, O; Prapas, I; Prapas, N; Tinelli, A; Tzallas, C, 2016) |
| "The efficacy of pathways inhibition and the combined effect of Everolimus (mTOR inhibitor) and Verapamil (CYP3A inhibitor) in ovarian hyperstimulation syndrome (OHSS) need to be tested." | 3.83 | The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study. ( Dalkalitsis, A; Georgiou, I; Kitsou, C; Kosmas, I; Lazaros, L; Mynbaev, O; Prapas, I; Prapas, N; Tinelli, A; Tzallas, C, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kitsou, C | 2 |
| Kosmas, I | 2 |
| Lazaros, L | 2 |
| Hatzi, E | 1 |
| Euaggelou, A | 1 |
| Mynbaev, O | 2 |
| Tournaye, H | 1 |
| Prapas, N | 2 |
| Prapas, I | 2 |
| Zikopoulos, K | 1 |
| Galani, V | 1 |
| Georgiou, I | 2 |
| Tzallas, C | 1 |
| Tinelli, A | 1 |
| Dalkalitsis, A | 1 |
2 other studies available for verapamil and Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous
| Article | Year |
|---|---|
Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Calcium Signaling; Cyclooxygenase 2 Inhibit | 2014 |
The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study.
Topics: Animals; Capillary Permeability; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Everolim | 2016 |